AstraZeneca eyes year-end filing for BP drug Baxdrostat

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-09-01 06:56 GMT   |   Update On 2025-09-01 06:56 GMT
Advertisement

Bengaluru: AstraZeneca plans to seek regulatory approval for its experimental blood pressure drug, baxdrostat, by the end of the year, a senior company executive stated. 

Ruud Dobber, president of AstraZeneca’s biopharmaceuticals unit, confirmed the timeline ahead of a presentation of advanced clinical trial data at a medical conference on Saturday. The company is targeting potential approvals in 2026, starting with the United States and the European Union.

Baxdrostat targets blood pressure-regulating hormone aldosterone, a novel approach compared with older treatments like diuretics and ACE inhibitors, which do not address hormonal drivers.

AstraZeneca expects peak annual sales for the drug to exceed $5 billion, Reuters
Keenly watched data showed that 2mg of baxdrostat, added to standard treatment, reduced systolic blood pressure by 9.8 millimetres of mercury (mmHg) from the baseline at 12 weeks, when adjusted for placebo, in patients with hard-to-control hypertension.
Advertisement
At the 1mg dose, that pressure exerted on the arteries by the heart's pumping action was lowered by 8.7 mmHg.
Physicians polled by TD Cowen wished to see a 10-12 mmHg fall in placebo-adjusted blood pressure, the brokerage said on Friday.
Mineralys Therapeutics' rival drug, lorundrostat, in March showed a placebo-adjusted reduction in systolic blood pressure by 9.1 mmHg at six weeks with a 50mg dose. The U.S. company also expects to submit data to the FDA by year-end.
"There's a huge acknowledgement that hypertension needs to be treated in a much more aggressive way," Dobber said.
High blood pressure affects over 1 billion people, according to the World Health Organization, and aggravates risk of heart attacks or strokes.
A small percentage of patients - 1.1% - taking baxdrostat developed hyperkalaemia, marked by high potassium levels in the blood. Hyperkalaemia was also observed with Mineralys' lorundrostat.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News